China Biologic suffers contaminated infusion

By Jeffrey Goldfarb Reuters  From Nasdaq (The author is a Reuters Breakingviews columnist.) HONG KONG, Aug 27 (Reuters Breakingviews) – China Biologic Products makes a good case for why it should go private. Instead of accepting one of two takeover…